DURECT (DRRX) Competitors $0.57 -0.02 (-3.44%) As of 07/25/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DRRX vs. APLT, RPTX, CRVO, ASRT, STRO, HOWL, SCLX, IKNA, BRNS, and MNOVShould you be buying DURECT stock or one of its competitors? The main competitors of DURECT include Applied Therapeutics (APLT), Repare Therapeutics (RPTX), CervoMed (CRVO), Assertio (ASRT), Sutro Biopharma (STRO), Werewolf Therapeutics (HOWL), Scilex (SCLX), Ikena Oncology (IKNA), Barinthus Biotherapeutics (BRNS), and MediciNova (MNOV). These companies are all part of the "pharmaceutical products" industry. DURECT vs. Its Competitors Applied Therapeutics Repare Therapeutics CervoMed Assertio Sutro Biopharma Werewolf Therapeutics Scilex Ikena Oncology Barinthus Biotherapeutics MediciNova Applied Therapeutics (NASDAQ:APLT) and DURECT (NASDAQ:DRRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations. Do analysts recommend APLT or DRRX? Applied Therapeutics presently has a consensus price target of $6.10, indicating a potential upside of 1,170.83%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Applied Therapeutics is more favorable than DURECT.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Applied Therapeutics 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50DURECT 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media favor APLT or DRRX? In the previous week, Applied Therapeutics had 2 more articles in the media than DURECT. MarketBeat recorded 3 mentions for Applied Therapeutics and 1 mentions for DURECT. DURECT's average media sentiment score of 1.87 beat Applied Therapeutics' score of 0.88 indicating that DURECT is being referred to more favorably in the news media. Company Overall Sentiment Applied Therapeutics Positive DURECT Very Positive Which has more risk and volatility, APLT or DRRX? Applied Therapeutics has a beta of 1.82, suggesting that its stock price is 82% more volatile than the S&P 500. Comparatively, DURECT has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Do insiders & institutionals believe in APLT or DRRX? 98.3% of Applied Therapeutics shares are owned by institutional investors. Comparatively, 28.0% of DURECT shares are owned by institutional investors. 1.6% of Applied Therapeutics shares are owned by company insiders. Comparatively, 3.2% of DURECT shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is APLT or DRRX more profitable? Applied Therapeutics has a net margin of 0.00% compared to DURECT's net margin of -91.54%. Applied Therapeutics' return on equity of -184.67% beat DURECT's return on equity.Company Net Margins Return on Equity Return on Assets Applied TherapeuticsN/A -184.67% -84.02% DURECT -91.54%-267.36%-64.00% Which has higher valuation & earnings, APLT or DRRX? DURECT has higher revenue and earnings than Applied Therapeutics. DURECT is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApplied Therapeutics$460K147.74-$105.62M-$0.43-1.12DURECT$2.03M8.68-$8.32M-$0.15-3.78 SummaryApplied Therapeutics beats DURECT on 10 of the 16 factors compared between the two stocks. Get DURECT News Delivered to You Automatically Sign up to receive the latest news and ratings for DRRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DRRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRRX vs. The Competition Export to ExcelMetricDURECTMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.24M$2.49B$5.69B$9.50BDividend YieldN/A1.65%4.58%4.01%P/E Ratio-3.789.0528.1020.05Price / Sales8.68612.51432.4890.19Price / CashN/A165.2136.2258.56Price / Book1.965.168.665.87Net Income-$8.32M$30.99M$3.25B$258.55M7 Day Performance6.00%7.74%4.22%3.73%1 Month Performance-8.69%16.27%10.51%11.75%1 Year Performance-66.02%-1.88%34.40%18.03% DURECT Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRRXDURECT1.1933 of 5 stars$0.57-3.4%N/A-65.6%$18.24M$2.03M-3.7880Positive NewsGap DownAPLTApplied Therapeutics4.4001 of 5 stars$0.46-0.4%$6.10+1,226.1%-90.8%$65.39M$460K-1.0730News CoverageAnalyst UpgradeRPTXRepare Therapeutics2.8661 of 5 stars$1.50-0.7%$4.50+200.0%-60.0%$64.77M$53.48M-0.50180CRVOCervoMed3.2514 of 5 stars$8.43+13.8%$22.57+167.8%-37.5%$64.49M$9.74M-3.874News CoverageAnalyst ForecastASRTAssertio2.3167 of 5 stars$0.70+3.3%$2.75+295.7%-49.7%$64.46M$124.96M-2.1720Positive NewsSTROSutro Biopharma4.162 of 5 stars$0.80+5.3%$6.11+664.3%-79.3%$64.19M$62.04M-0.27240News CoverageHOWLWerewolf Therapeutics4.0485 of 5 stars$1.40-0.7%$8.33+495.2%-50.4%$63.27M$1.88M-0.8440SCLXScilex2.3844 of 5 stars$8.60-2.9%$455.00+5,190.7%-79.9%$61.59M$56.59M-0.3080News CoverageIKNAIkena Oncology2.8301 of 5 stars$1.27flat$3.00+136.2%-14.9%$61.29M$9.16M-1.4870News CoverageEarnings ReportAnalyst ForecastStock SplitHigh Trading VolumeBRNSBarinthus Biotherapeutics3.6737 of 5 stars$1.97+31.5%$6.25+217.3%+22.6%$60.41M$14.97M-1.20107Positive NewsGap UpHigh Trading VolumeMNOVMediciNova1.6029 of 5 stars$1.26+2.4%$7.00+455.6%+12.3%$60.33M$1M-5.4810News CoverageAnalyst ForecastGap Up Related Companies and Tools Related Companies APLT Competitors RPTX Competitors CRVO Competitors ASRT Competitors STRO Competitors HOWL Competitors SCLX Competitors IKNA Competitors BRNS Competitors MNOV Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRRX) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DURECT Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share DURECT With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
